Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.16
+0.73005.87%
Post-market: 13.210.0524+0.40%19:56 EDT
Volume:7.07M
Turnover:93.15M
Market Cap:10.50B
PE:-11.77
High:13.53
Open:12.69
Low:12.57
Close:12.43
52wk High:30.05
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.98
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:16.66
PE(LYR):-9.11

Loading ...

Summit Therapeutics Announces Availability of Ivonescimab Harmoni Trial Update Press Release

Reuters
·
Jul 22

Summit Therapeutics - FDA Accepts Bla for Ivonescimab; Pdufa Date November 14, 2026

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Phase Iii Harmoni Study Shows Statistically Significant Pfs Benefit

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Ivonescimab Continues to Show Acceptable Safety Profile; no New Safety Signals

THOMSON REUTERS
·
Jul 22

Summit Therapeutics - Ivonescimab Plus Chemotherapy Shows Positive Os Trend in Asian and Western Patients

THOMSON REUTERS
·
Jul 22

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase Iii Harmoni Study

THOMSON REUTERS
·
Jul 22

Analysts Are Bullish on These Healthcare Stocks: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT)

TIPRANKS
·
Jul 22

What Comes After Merck's Keytruda? the Race for the Next Standard Cancer Treatment.

Dow Jones
·
Jul 20

Earning Preview: Summit Therapeutics PLC this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Earnings Agent
·
Jul 17

Kalshi to Allow Bets on Clinical Trials, FDA Decisions

Reuters
·
Jul 16

Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Dow Jones
·
Jul 16

Summit Therapeutics Schedules Q2 2026 Results, Operational Update Call

Reuters
·
Jul 16

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Simply Wall St.
·
Jul 15

Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil

MT Newswires Live
·
Jul 14

Summit Therapeutics Signs Agreement to Sell Phase Iii Asset Ridinilazole to Biossil, Inc.

THOMSON REUTERS
·
Jul 14

Summit Therapeutics - to Receive $500,000 Upfront and up to $104.5 Mln in Milestones Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?

Simply Wall St.
·
Jun 25

UK Vehicle Production Rebounds in May, Halting Four-Month Decline

Deep News
·
Jun 25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 22

Summit Therapeutics shareholders approve 8 million-share increase to 2020 stock incentive plan

Reuters
·
Jun 13